Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan O. Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini

Blood (2017) 130 (5): 597–605.

https://doi.org/10.1182/blood-2017-03-771220

Published: 2017

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, PhD, Michael J Hanley, PhD, R. Donald Harvey, PharmD, Ashraf Z Badros, MD, Brea C. Lipe, MD, Vishal Kukreti, Jesus G. Berdeja, MD, Huyuan Yang, PhD, Ai-Min Hui, MD PhD, Xiaoquan Zhang, MD PhD, Karthik Venkatakrishnan, PhD, Ajai Chari, MD

Blood (2015) 126 (23): 4227.

https://doi.org/10.1182/blood.V126.23.4227.4227

Published: 2015

Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Blood (2015) 126 (23): 727.

https://doi.org/10.1182/blood.V126.23.727.727

Published: 2015

Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD

Blood (2014) 124 (21): 3450.

https://doi.org/10.1182/blood.V124.21.3450.3450

Published: 2014

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang, Andrzej J. Jakubowiak, Jacob P. Laubach, R. Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Sagar Lonial

Blood (2014) 124 (7): 1038–1046.

https://doi.org/10.1182/blood-2014-01-548826

Published: 2014

Includes: Supplemental data

Journal Articles

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Shaji K. Kumar, William I. Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu, Yaping Shou, Ruben Niesvizky

Blood (2014) 124 (7): 1047–1055.

https://doi.org/10.1182/blood-2014-01-548941

Published: 2014

Includes: Supplemental data

Journal Articles

AL Amyloidosis: Development Of a Conceptual Model and a Symptom Diary

Emuella Flood, David Seldin, Ai-Min Hui, Deborah Berg, Huamao Mark Lin

Blood (2013) 122 (21): 5609.

https://doi.org/10.1182/blood.V122.21.5609.5609

Published: 2013

Journal Articles

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G. Richardson, MD, Craig C Hofmeister, MD, Cara A Rosenbaum, MD, Myo Htut, MD, David H. Vesole, MD, PhD, Jesus Berdeja, MD, Michaela Liedtke, MD, Ajai Chari, MD, Stephen D Smith, MD, Daniel Lebovic, MD, Deborah Berg, RN, MSN, Eileen Liao, Ph.D, Neeraj Gupta, Ph.D, Alessandra Di Bacco, Ph.D, Jose Estevam, BS, MS, Ai-Min Hui, Rachid Baz, MD

Blood (2013) 122 (21): 535.

https://doi.org/10.1182/blood.V122.21.535.535

Published: 2013

Journal Articles

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Shaji K. Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Mehdi Hamadani, MD, A. Keith Stewart, MBA, MB, CHB, Vivek Roy, M.D., Parameswaran Hari, MBBS, MD, MRCP, Robert Vescio, MD, Deborah Berg, RN, MSN, Jianchang Lin, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 332.

https://doi.org/10.1182/blood.V120.21.332.332

Published: 2012

Journal Articles

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Giampaolo Merlini, Vaishali Sanchorawala, Jeffrey A. Zonder, MD, Vishal Kukreti, MD, Stefan O Schonland, MD, Arnaud Jaccard, Angela Dispenzieri, MD, Adam D. Cohen, Deborah Berg, RN, MSN, Guohui Liu, PhD, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, PhD, Giovanni Palladini, Raymond L. Comenzo, MD

Blood (2012) 120 (21): 731.

https://doi.org/10.1182/blood.V120.21.731.731

Published: 2012

Journal Articles

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Sarit Assouline, Julie E. Chang, MD, Bruce D. Cheson, MD, Robert Rifkin, MD, Solomon Hamburg, MD, PhD, Ruben Reyes, MD, Ai-Min Hui, MD, PhD, Jiang Yu, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Yaping Shou, Peter Martin, MD

Blood (2012) 120 (21): 3646.

https://doi.org/10.1182/blood.V120.21.3646.3646

Published: 2012

Journal Articles

MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study

Sarit Assouline, MD, Julie Chang, MD, Robert Rifkin, MD, Ai-Min Hui, MD, Deborah Berg, RN, MSN, Neeraj Gupta, PhD, Yingmei Xi, PhD, Alessandra Di Bacco, PhD, Peter Martin, MD

Blood (2011) 118 (21): 2672.

https://doi.org/10.1182/blood.V118.21.2672.2672

Published: 2011

Journal Articles

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

Shaji Kumar, MD, William I Bensinger, MD, Craig B. Reeder, MD, Todd M. Zimmerman, MD, James R. Berenson, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Ai-Min Hui, MD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 816.

https://doi.org/10.1182/blood.V118.21.816.816

Published: 2011

Journal Articles

Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study

Paul G. Richardson, MD, Rachid Baz, MD, Luhua Wang, MD, Andrzej J Jakubowiak, MD, PhD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Ai-Min Hui, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 301.

https://doi.org/10.1182/blood.V118.21.301.301

Published: 2011

Journal Articles

Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Paul G. Richardson, MD, Sagar Lonial, MD, Ruben Niesvizky, MD, Ai-Min Hui, MD, Deborah Berg, RN, MSN, Neeraj Gupta, PhD, Guohui Liu, PhD, Alessandra Di Bacco, PhD, Shaji Kumar, MD

Blood (2011) 118 (21): 479.

https://doi.org/10.1182/blood.V118.21.479.479

Published: 2011

NARROW

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

AL Amyloidosis: Development Of a Conceptual Model and a Symptom Diary

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study

Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only